Advertisement
U.S. Markets closed

Roche Holding AG (RHHBY)

Other OTC - Other OTC Delayed Price. Currency in USD
31.92+0.61 (+1.95%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close31.31
Open31.53
BidN/A x N/A
AskN/A x N/A
Day's Range31.53 - 31.95
52 Week Range31.13 - 40.48
Volume1,770,444
Avg. Volume1,828,936
Market Cap205.514B
Beta (5Y Monthly)0.15
PE Ratio (TTM)16.04
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.39 (4.45%)
Ex-Dividend DateMar 14, 2024
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for RHHBY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ROCHE HOLDINGS AG SPN ADR EACH
    Analyst Report: Roche Holding AGRoche Holding AG operates through two segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment focuses on oncology, immunology, ophthalmology, infectious diseases and neuroscience, and the Diagnostics segment specializes in in vitro diagnostics. Headquartered in Basel, Switzerland, the company was founded by Fritz Hoffmann-La Roche in 1896. The company has approximately 103,605 employees. Roche has substantial market shares in oncology treatments and in vitro diagnostics, and is working to combine its expertise in these areas to develop personalized medicines based on the genetic characteristics of patients. In addition to organic growth, the company has a growth-by-acquisition strategy.
    Rating
    Fair Value
    Economic Moat
    25 days agoArgus Research
View more